Business
PRTC Presents Data at ACNP Conference For LYT-300
PRTC Presents Data at ACNP Conference For LYT-300.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9033U\n PureTech Health PLC\n 08 December 2021\n \n \n \n \n 8 December 2021\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions\n \n \n \n \n \n Data demonstrating ability to achieve systemic exposure following oral administration shared at American College of Neuropsychopharmacology (ACNP) Annual Meeting\n \n \n \n \n \n Results support potential of PureTech's GlyphTM technology platform to enable oral administration for a range of therapeutics\n \n \n \n \n \n LYT-300 was recently advanced into a Phase 1 clinical study\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of preclinical proof-of-concept data at the 60th American College of Neuropsychopharmacology (ACNP) Annual Meeting that support the clinical advancement of LYT-300 (oral allopregnanolone), PureTech's wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 was \n \n \n recently advanced into a Phase 1 clinical study\n \n \n , which is designed to characterize the safety, tolerability and PK of orally administered LYT-300 in healthy volunteers and is expected to read out in the second half of 2022. \n \n \n \n \n \n LYT-300 is an oral form of allopregnanolone. Allopregnanolone is a natural neurosteroid that is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, which are known to play a key biological role in depression, epilepsy and other neurological and neuropsychological conditions. Natural allopregnanolone has poor oral bioavailability, thus limiting its development as a therapeutic. An injectable formulation of allopregnanolone is approved by the United States Food and Drug Administration (FDA) as a 60-hour infusion for the treatment of post-partum depression, t...